Kosho Murayama

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 3

Top Topics

Cross Sectional

Top Venues

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, Ko Sugibayashi, Kosho Murayama, Noboru Yamamoto
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study. International journal of clinical oncology 27 (12) (2022)
Tomohiro Nishina, Tomoko Fujita, Naoto Yoshizuka, Ko Sugibayashi, Kosho Murayama, Yasutoshi Kuboki
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. BMJ open 12 (10) (2022)
Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi, Hirohiko Shibayama, Junji Suzumiya, Kazuhito Yamamoto, Satoshi Ichikawa, Koji Kato, Kyoya Kumagai, Priti Patel, Sakura Iizumi, Nobuya Hayashi, Hisashi Kawasumi, Kosho Murayama, Hirokazu Nagai
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer science 112 (6) (2021)